Evidence map›Paper›PMID 41492454›Full record

ArticleBiological psychiatry global open science2026

Variant in a Taste Receptor Locus Tied to Changes in the Use of Insomnia Medication.

Gudmundur Einarsson, Hannes K Arnason, Rosa S Gisladottir, Gyda Bjornsdottir, Thorgeir E Thorgeirsson, Astros Skuladottir, G Bragi Walters, Saedis Saevarsdottir, Magnus K Magnusson, Gisli H Halldorsson and 14 more

Abstract read
In one paragraph

Article in Biological psychiatry global open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Gudmundur EinarssonAmgen deCODE Genetics, Reykjavik, Iceland.
Hannes K ArnasonAmgen deCODE Genetics, Reykjavik, Iceland.
Rosa S GisladottirAmgen deCODE Genetics, Reykjavik, Iceland.
Gyda BjornsdottirAmgen deCODE Genetics, Reykjavik, Iceland.
Thorgeir E ThorgeirssonAmgen deCODE Genetics, Reykjavik, Iceland.
Astros SkuladottirAmgen deCODE Genetics, Reykjavik, Iceland.
G Bragi WaltersAmgen deCODE Genetics, Reykjavik, Iceland.
Saedis SaevarsdottirAmgen deCODE Genetics, Reykjavik, Iceland.
Magnus K MagnussonAmgen deCODE Genetics, Reykjavik, Iceland.
Gisli H HalldorssonAmgen deCODE Genetics, Reykjavik, Iceland.
Audunn S SnaebjarnarsonAmgen deCODE Genetics, Reykjavik, Iceland.
Hafsteinn EinarssonAmgen deCODE Genetics, Reykjavik, Iceland.
Gardar SveinbjornssonAmgen deCODE Genetics, Reykjavik, Iceland.
Hannes HelgasonAmgen deCODE Genetics, Reykjavik, Iceland.
Vinicius TraganteAmgen deCODE Genetics, Reykjavik, Iceland.
Gudrun A JonsdottirAmgen deCODE Genetics, Reykjavik, Iceland.
Hildur M AegisdottirAmgen deCODE Genetics, Reykjavik, Iceland.
Ingileif JonsdottirAmgen deCODE Genetics, Reykjavik, Iceland.
Thorarinn GislasonFaculty of Medicine, University of Iceland, Reykjavik, Iceland.
Gudmar ThorleifssonAmgen deCODE Genetics, Reykjavik, Iceland.
Patrick SulemAmgen deCODE Genetics, Reykjavik, Iceland.
Hreinn StefanssonAmgen deCODE Genetics, Reykjavik, Iceland.
Daniel F GudbjartssonAmgen deCODE Genetics, Reykjavik, Iceland.
Kari StefanssonAmgen deCODE Genetics, Reykjavik, Iceland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Zopiclone and zolpidem are widely prescribed hypnotic medications for insomnia, sharing similar efficacy but differing in side-effect profiles, particularly concerning taste disturbances. Identifying genetic predictors of intolerance to these medications could inform personalized treatment strategies. Methods: We conducted a genome-wide association study to identify genetic variants associated with switching between zopiclone and zolpidem in 57,669 Icelanders, using electronic prescription data from Iceland (2003-2020), and 6590 British individuals from the UK Biobank (1990-2017). We included individuals who had received at least 3 prescriptions of either drug. We also investigated data on bitter taste perception using quinine taste test data from 2238 Icelandic individuals. Results: A common sequence variant, rs6488335-G, within the Conclusions: Our findings indicate that carriers of the rs6488335-G variant, particularly homozygous women, were more likely to switch from zopiclone to zolpidem, potentially due to heightened sensitivity to taste-related side effects. Preemptive genetic testing could guide clinicians in prescribing zolpidem over zopiclone for individuals at risk, thereby reducing health care visits and improving treatment adherence.

Indexed as

Electronic health recordsGeneticsPersonalized medicinePharmacogenomicsZ-drugs

Identifiers

PMID41492454
PMCPMC12765185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.